Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Skyline Therapeutics (us) Inc.

Clinical trials sponsored by Skyline Therapeutics (us) Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a One-Time gene injection ease the burden of wet AMD? Results expected Jan 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

Can a One-Time gene injection ease the burden of wet AMD?

Disease control Recruiting now

This phase 1/2 trial tests SKG0106, a gene therapy injected into the eye, in people with wet age-related macular degeneration (nAMD). The treatment aims to help the eye produce proteins that block abnormal blood vessel growth, potentially reducing the need for frequent anti-VEGF …

Phase 1/2 • Sponsor: Skyline Therapeutics (US) Inc. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC